Obesity – Talk Bio

Jesper Høiland Joins Alva Therapeutics’ Board of Directors

4 days ago talkbio0Tagged Alva Therapeutics, board of directors, Clinical Development, Diabetes Mellitus, Non-Insulin-Dependent, incretin secretagogue, Novo Nordisk, Obesity, Oral cavity, pharmaceutical commercialization

Alva Therapeutics; Board of Directors; Novo Nordisk; Type 2 diabetes; obesity; oral incretin secretagogue; clinical development; pharmaceutical commercialization

Jesper Høiland Joins Alva Therapeutics’ Board of Directors

4 days ago talkbio0Tagged Alva Therapeutics, board of directors, Clinical Development, Diabetes Mellitus, Non-Insulin-Dependent, incretin secretagogue, Novo Nordisk, Obesity, Oral cavity, pharmaceutical commercialization

Alva Therapeutics; Board of Directors; Novo Nordisk; Type 2 diabetes; obesity; oral incretin secretagogue; clinical development; pharmaceutical commercialization

Recent Developments on Vinay Prasad’s Leaked FDA Memo, Alzheimer’s Disease Updates, and Next-Gen Obesity Drugs

4 days ago talkbio0Tagged Alzheimer 's disease, Cessation of life, Child, COVID19 (disease), next-generation, Obesity, research, United States Food and Drug Administration, Vaccines, Vinay Prasad FDA memo

Vinay Prasad FDA memo; COVID-19 vaccine deaths children; FDA vaccine approval changes; Alzheimer’s disease research 2025; obesity drugs next generation; COVID-19 vaccine safety controversy; FDA vaccine policy overhaul

Recent obesity and IL-6 program updates for Fractyl, Helicore, and Tiziana

4 days ago talkbio0Tagged Autoimmune, Discontinuation (procedure), Fractyl Health, Glucagon-Like Peptide 1, Helicore, interleukin-6, Obesity, REVEAL-1, Revita, Tiziana Life Sciences, weight loss maintenance

Fractyl Health; Revita; REVEAL-1; weight loss maintenance; GLP-1 discontinuation; Helicore; Tiziana Life Sciences; IL-6; autoimmune; obesity

Researchers Advance Toward Matching Patients with the Most Effective GLP-1 Drug for Personalized Obesity Treatment

2 weeks ago talkbio0Tagged aspects of adverse effects, drug response, Genetic screening method, Glucagon-Like Peptide 1, Machine Learning, Mayo Clinic, MyPhenome, Obesity, personalized care, Precision Medicine, Prediction, Treatment Adherence

GLP-1; precision medicine; obesity; drug response prediction; genetic test; personalized care; side effects; machine learning; MyPhenome; Mayo Clinic; treatment adherence

Pressure On, Purpose Questioned as Second Round of FDA Priority Review Vouchers Revealed

3 weeks ago talkbio0Tagged Anemia, Sickle Cell, Biosimilars, Commissioner 's National Priority Voucher, Drug Approval, drug price, eli lilly, erbB-2 Receptor, Malignant neoplasm of lung, Obesity, Priority Review, public health medicine (field), Tuberculosis, Drug-Resistant, United States Food and Drug Administration, voucher program

FDA; Commissioner’s National Priority Voucher; priority review; drug approval; voucher program; Eli Lilly; Novo Nordisk; her2 lung cancer; obesity drugs; drug-resistant tuberculosis; sickle cell disease; biosimilars; public health; drug pricing; regulatory controversy

Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama

3 weeks ago talkbio0Tagged Acquisition, bidding war, CVR, Glucagon-Like Peptide 1, Metsera, Nordisk, Obesity, Pfizer, regulatory certainty

Pfizer; Metsera; acquisition; Novo Nordisk; bidding war; obesity drugs; GLP-1; CVR; regulatory certainty

Zealand Pharma Pauses Development of GLP-1/GLP-2 Dual Agonist Dapiglutide for Obesity

3 weeks ago talkbio0Tagged Agonist, Clinical Development, Dapiglutide, drug market, GLP-1/GLP-2, Obesity, obesity therapy, petrelintide, pipeline management, Zealand Pharma

Zealand Pharma; dapiglutide; GLP-1/GLP-2 dual agonist; obesity therapy; clinical development; obesity drug market; pipeline management; petrelintide; survodutide